MBio Diagnostics

MBio Diagnostics is a biotech company leading a new era in rapid, on-the-spot clinical diagnostics and sample testing.

MBio Diagnostics is developing a portfolio of in vitro diagnostic tests for medical settings where reliable, fast results are vital in making time-critical decisions.

MBio Diagnostics was founded in 2009 by Chris Myatt. The company is headquartered in Boulder, Colorado.

 

MBio Diagnostics is the innovator of the proprietary LightDeck platform that delivers highly sensitive, on-the-spot results in minutes. It operates an internal diagnostics division, Brava Diagnostics, that is developing a robust portfolio of IVD tests and we collaborate with commercial, academic and government partners.

 

The MBio platform brings remarkable simplicity of use and speed to a broad range of test modalities, from protein arrays and nucleic acid detection to cellular analysis. MBio’s approach is differentiated from other rapid test methods: it is low cost (injection-molded plastic consumables), highly reproducible, and readily scalable to large volume manufacturing.

 

MBio Diagnostics is backed by HESKA, Incubic Venture Capital, National Science Fund, Capital for Founders (CFF) LLC, and others. The company has raised a total of $20.9M to date.

 

 

  • Year founded: 2009
  • Funding Info: $20.9M over 5 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Boulder
  • State: Colorado
  • Country: United States
Related businesses